An interventional study of Lens 1 (ocufilcon D) and Lens 2 (somofilcon A) in Hyperopia and Myopia, sponsored by CooperVision, Inc.. Completed at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-08.
Sponsored by CooperVision, Inc. (part of CooperCompanies) · Not applicable, Interventional, and Treatment
The aim of this study is to compare the short-term clinical performance of two soft contact lenses.
The aim of this study is to evaluate the short-term clinical performance of two soft contact lenses when compared to each other after 15 minutes of daily wear each.
156 studies on the registry are indexed under Hyperopia; 20 are open to participants now.
This study's enrollment of 52 is below the median of 60 across 125 interventional studies indexed under Hyperopia.
Browse Hyperopia studies →CooperVision, Inc. is the lead sponsor of 39 studies on the registry; none are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 31 (94%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants will wear lens 1 for 15 minutes (Period 1).
Device: Lens 1 (ocufilcon D)
All participants will wear lens 2 for 15 minutes (Period 2).
Device: Lens 2 (somofilcon A)
15 minutes of daily wear
15 minutes of daily wear
Subjective Overall Score
The primary outcome measure for this study is the subjective overall score on a scale of 0-100 (0= Extremely poor, unmanageable, cannot use lenses, 100= Excellent, highly impressed with these lenses overall).
Time frame: At the end of 15 minutes of daily wear
Subjective Vision
The secondary outcome measure for this study is the subjective vision on a scale of 0-100 (0= Extremely poor, intolerable, lenses cannot be worn, 100= Excellent, unaware of any visual loss).
Time frame: At the end of 15 minutes of daily wear
Subjective Comfort
The secondary outcome measure for this study is the subjective comfort on a scale of 0-100 (0= Extremely uncomfortable, causes pain, cannot be tolerated, 100= Excellent, cannot be felt).
Time frame: At the end of 15 minutes of daily wear
| Milestone | Lens 1 (Ocufilcon D) Then Lens 2 (Somofilcon A) |
|---|---|
| Started | 52 |
| Completed | 50 |
| Not completed | 2 |
| Withdrew: Severe environmental allergies | 1 |
| Withdrew: Eligibility criteria | 1 |
| Milestone | Lens 1 (Ocufilcon D) Then Lens 2 (Somofilcon A) |
|---|---|
| Started | 50 |
| Completed | 50 |
| Not completed | 0 |
The primary outcome measure for this study is the subjective overall score on a scale of 0-100 (0= Extremely poor, unmanageable, cannot use lenses, 100= Excellent, highly impressed with these lenses overall).
| Units on Scale | Lens 1 (Ocufilcon D) | Lens 2 (Somofilcon A) |
|---|---|---|
| Subjective Overall Score | 80.8 ± 16.4 | 82.9 ± 15.9 |
The secondary outcome measure for this study is the subjective vision on a scale of 0-100 (0= Extremely poor, intolerable, lenses cannot be worn, 100= Excellent, unaware of any visual loss).
| units on a scale | Lens 1 (Ocufilcon D) | Lens 2 (Somofilcon A) |
|---|---|---|
| Subjective Vision | 80.9 ± 17.6 | 83.1 ± 15.9 |
The secondary outcome measure for this study is the subjective comfort on a scale of 0-100 (0= Extremely uncomfortable, causes pain, cannot be tolerated, 100= Excellent, cannot be felt).
| units on a scale | Lens 1 (Ocufilcon D) | Lens 2 (Somofilcon A) |
|---|---|---|
| Subjective Comfort | 87.6 ± 15.5 | 84.5 ± 19.0 |
Collected over Through study completion (single visit, approximately 30 minutes). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lens 1 (Ocufilcon D) | 0/50 (0%) | 0/50 (0%) | 0/50 (0%) |
| Lens 2 (Somofilcon A) | 0/50 (0%) | 0/50 (0%) | 0/50 (0%) |
| Age, Continuous(Years) | All Study Participants |
|---|---|
| Mean | 41.3 ± 14.9 |
| Sex: Female, Male(Participants) | All Study Participants |
|---|---|
| Female | 34 |
| Male | 16 |
| Race and Ethnicity Not Collected(Participants) | All Study Participants |
|---|
PDFs hosted by the registry, ClinicalTrials.gov.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.